Beyond Weight Loss: What GLP-1 Medications Might Really Do for Your Body

Most people come to us for one reason: they want to lose weight. But lately, they walk in with a longer list of questions. They've seen the posts. These medications fight cancer. They sharpen your memory. They turn off "food noise." Is any of it real?

Here's the honest answer. Some of it is promising, some of it we see every day in clinic, and some of it is years away from being proven. But there's one idea that ties all of it together: when the body starts to heal from obesity, it steps off the sick path and onto a healthy one — and as it does, other problems tend to fade on their own.

The big question is whether these extra benefits come from the medication itself, or simply from the weight loss it causes. And the truth is, we don't fully know yet.

Why "drug or weight loss" is the real question

Excess body fat isn't just stored energy. It drives inflammation — a low, constant irritation throughout the body — and it makes insulin, the hormone that manages blood sugar, work less efficiently. Lose the excess fat, and both of those improve.¹ Blood pressure drops. The liver recovers. The body calms down.

So when we see a "secondary benefit" from a GLP-1 medication, we run into a real puzzle: is the drug doing something special, or is it just that losing weight makes people healthier? For most of these benefits, we genuinely can't separate the two yet. Keep that question in mind — it explains everything that follows.

Food noise: the one we actually see

Of all these effects, this is the one I hear about most.

"Food noise" is the constant background chatter in your head about food — the cravings, the snacking, the pull toward the kitchen when you're stressed or bored rather than hungry. For a lot of people, it never really shuts off.

The patients who notice the biggest change are exactly who you'd expect: the snackers, the emotional eaters, the ones who eat for comfort instead of hunger. They describe something striking — an almost indifference to food. The noise quiets down.² And that quiet is powerful, because it's what finally lets everything else work. When you're not fighting cravings all day, eating well and staying consistent gets a whole lot easier.

I'll be straight with you: "food noise" is something we observe clinically, not yet something we measure with a precise test. But we see it enough that it's hard to ignore. And it works best the way all real change works — paired with good nutrition, coaching, and a team around you. The medication quiets the noise. You and your team still do the work.

Cancer: a real signal we can't fully explain yet

This is the one that surprises people. Over the past few decades, we've seen more cancers showing up in younger adults. During those same decades, obesity has climbed right alongside it. That's not a coincidence we can ignore — excess fat is a known driver of several cancers.

So researchers asked a fair question: if these drugs reduce obesity, do they reduce cancer too? Some large studies suggest they might. In one analysis of millions of patients, people taking GLP-1 medications had a lower overall cancer risk, with the clearest reductions in endometrial, ovarian, and one type of brain tumor called meningioma.³

But here's where I tell you the whole truth, not just the good part. That same study found a slight, uncertain hint of higher kidney cancer risk — small enough that it may be nothing, but honest research reports it anyway.³ And in another large study, the drugs beat insulin at lowering cancer risk but showed no extra benefit over metformin, an older medication.⁴ That points right back to our central question: a lot of the benefit may come from the weight and metabolic improvement, not the specific drug.

So where does that leave us? It's a genuinely interesting signal, and it's biologically plausible. But no completed trial has shown these medications prevent cancer. Interesting is not the same as proven.

The brain: promising, but not there yet

You may have seen claims that these drugs protect against Alzheimer's or Parkinson's. The early picture is intriguing. In lab and animal studies, GLP-1 signaling looks protective to brain cells, and some observational data hint at lower rates of dementia in people taking these medications.⁵

But intriguing isn't enough. The real test is a randomized trial — where you compare the drug head-to-head against a placebo — and so far those results have been mixed to negative for actually preventing cognitive decline.⁵ The honest stance is simple: this is a research question, not a reason to take these medications. We don't prescribe them for the brain, and neither should anyone else right now.

What this means for you

If you're considering a GLP-1 medication, here's how we'd frame it. Weight loss is the goal. Everything else is a bonus you'll happily take but shouldn't count on.

And remember what these drugs actually are: a tool, not the whole plan. The foundation is still the foundation — nutrition, movement, sleep, managing stress. The medication can quiet the noise and make the foundation easier to build, but it doesn't replace it. The people who do best are the ones who use the tool and do the work, with a team supporting them. If you're weighing whether one of these is right for you, that's a conversation to have with your doctor.

Bottom line

When the body heals from obesity, good things tend to follow. We're still learning how much is the medicine and how much is the weight loss — but the direction is right, and that's what matters most.

References

1. Drucker DJ. The expanding landscape of GLP-1 medicines. Nature Medicine. 2026;32(1):47–57. PubMed

   
   

2. Ameer F, Villacres NY, Bustos D, et al. Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review. Journal of Diabetes & Metabolic Disorders. 2025;24:253. Full text

   
   

3. Dai H, Li Y, Lee YA, et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology. 2025;11(10):1186–1193. PubMed

   
   

4. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Network Open. 2024;7(7):e2421305. PubMed

   
   

5. De Giorgi R, Ghenciulescu A, Yotter C, Taquet M, Koychev I. Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2025;96(9):870–883. PubMed

About the author

Edward Orshansky, M.D. is board-certified in Family Medicine, an AOA Honor Medical Society member, and the Founder of formidableMD. With 10+ years across Hospital Medicine, Urgent Care, and Primary Care — and having lost 85 lbs himself — his mission is to help patients reach their healthiest selves before they end up as hospital patients. His clinical focus areas are weight management, longevity, and hormonal health. Doximity

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.